The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

Abstract

The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is presented.

Keywords

• off-label use
• hemodynamic angina
• trimetazidine